...majority of the patients were treated with R-CHOP [rituximab, cyclophosphamide, hydroxydaunorubicin (doxorubicin), Oncovin (vincristine) and prednisolone]...coexpression of MYC and BCL2 using a combination of MYC ≥60% with BCL2 ≥50% or >70% was associated with inferior PFS (HR 2.83 (1.12 to 7.20), p=0.035 and HR 2.84 (1.10 to 7.36), p=0.041, respectively) (figure 2C,D).

...152 primary DLBCL patients treated with R-CHOP or R-CHOP-like regimen....Dual protein expression (DPE) of BCL2 and MYC was detected in 9.5% of the cases. DPE lymphomas were evenly distributed between the subtypes, and they had adverse prognostic significance independent of IPI and molecular subtype (Figure 1D).